Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation
Conditions: COVID 19; SARS-CoV 2; Pneumonia Interventions: Drug: Mavrilimumab; Drug: Placebos Sponsors: The Cleveland Clinic; Kiniksa Pharmaceuticals, Ltd. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials